Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia
- 11 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 34 (10), 2766-2775
- https://doi.org/10.1038/s41375-020-0850-9
Abstract
The ideal stem cell graft source remains unknown in haploidentical haematopietic cell transplantation (haplo-HCT) with posttransplantation cyclophosphamide (PTCy). This study compared outcomes of bone marrow (BM) versus peripheral blood (PB) stem cell graft for haplo-HCT in acute lymphoblastic leukemia (ALL). A total of 314 patients with ALL (BM—157; PB—157) were included in this study. The cumulative incidence of engraftment at day 30 was higher in the PB group compared with BM (93% vs. 88%, p < 0.01). The incidences of acute graft-versus-host disease (GVHD) and chronic GVHD were not significantly different between the study cohorts. In the multivariate analysis, there were tendencies toward a higher incidence of grade II–IV acute GVHD (hazard ratio (HR) = 1.52, p = 0.07), chronic GVHD (HR = 1.58, p = 0.05), and nonrelapse mortality (NRM) (HR = 1.66, p = 0.06) in patients receiving PB versus BM graft, respectively. The use of PB grafts was associated with lower leukemia-free survival (LFS) (HR = 1.43, p = 0.05), overall survival (OS) (HR = 1.59, p = 0.02), and GVHD-free, relapse-free survival (GRFS) (HR = 1.42, p = 0.03) compared with BM grafts. There was no difference in relapse incidence (HR = 1.23, p = 0.41) between the study groups. In conclusion, use of BM graft results in better survival after haplo-HCT with PTCy in patients with ALL, compared with PB stem cell graft.This publication has 37 references indexed in Scilit:
- Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMTLeukemia, 2020
- Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic MalignanciesClinical Hematology International, 2019
- Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1Blood Advances, 2017
- A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemiaJournal of Hematology & Oncology, 2017
- Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideHaematologica, 2016
- Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute LeukemiaTransplantation and Cellular Therapy, 2016
- Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annuallyBone Marrow Transplantation, 2016
- Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk IndexTransplantation and Cellular Therapy, 2015
- Modern approaches to HLA-haploidentical blood or marrow transplantationNature Reviews Clinical Oncology, 2015
- Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemiaBlood, 2015